 "Remdesivir prices may rise after Gilead gets full authorisation from USFDA")
Prices of a key drug used to treat hospitalised Covid-19 patients, remdesivir, may rise once the innovator, Gilead, gets a full approval from the US drug regulator, said industry sources. Currently, generic manufacturers make and sell remdesivir in India under a voluntary licensing agreement and are not required to pay any royalty to the innovator.
“This is because remdesivir is an investigational drug and not approved as a therapy for Covid-19. It has an emergency use authorisation from the USFDA and also the Indian regulator in the wake of the pandemic. Gilead had indicated while signing the licensing agreement that they
